-
1.发明申请公开(公告)号：US20070287713A1
公开(公告)日：2007-12-13
申请号：US11779319
申请日：2007-07-18
申请人： Peter Cheng , Sean Chen , Pratik Devasthale , Charles Ding , Timothy Herpin , Shung Wu , Hao Zhang , Wei Wang , Xiang-Yang Ye
发明人： Peter Cheng , Sean Chen , Pratik Devasthale , Charles Ding , Timothy Herpin , Shung Wu , Hao Zhang , Wei Wang , Xiang-Yang Ye
IPC分类号： A61K31/41 , A61K31/42 , A61K31/44 , A61K31/445 , A61K31/4965 , A61K31/497 , A61K31/505 , A61P3/10 , C07D239/02 , C07D257/00 , C07D263/30 , C07D271/06 , C07D401/02 , C07D403/02 , C07D413/02
CPC分类号： C07D413/12 , C07D413/14
摘要： wherein Z1 is (CH2)q or C═O; Z2 is (CH2)p or C═O; D is —CH═ or C═O or (CH2)m where m is 0, 1, 2 or 3; n=0, 1 or 2; p=1 or 2; q=0, 1 or 2; Q is C or N; A is (CH2)x where x is 1 to 5, or A is (CH2)x1, where x1 is 1 to 5 with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A is —(CH2)x2—O—(CH2)x3— where x2 is 0 to 5 and x3 is 0 to 5, provided that at least one of x2 and x3 is other than 0; B is a bond or is (CH2)x4 where x4 is 1 to 5; X is CH or N; X2 is C, N, O or S; X3 is C, N, O or S; X4 is C, N, O or S; X5 is C, N, O or S; X6 is C, N, O or S; provided that at least one of X2, X3, X4 X5 and X6 is N; and at least one of X2, X3, X4 X5 and X6 is C. R1 is H or alkyl; R2 is H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; R2a, R2b and R2c may be the same or different and are selected from H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; and R3, E, Z and Y are as defined herein.
-
2.发明申请公开(公告)号：US20050119312A1
公开(公告)日：2005-06-02
申请号：US11016183
申请日：2004-12-17
申请人： Peter Cheng , Sean Chen , Charles Ding , Timothy Herpin
发明人： Peter Cheng , Sean Chen , Charles Ding , Timothy Herpin
IPC分类号： A61K31/41 , A61K31/42 , A61K31/435 , A61K31/50 , A61K31/52 , C07D233/54 , C07D249/06 , C07D263/32 , C07D271/06 , C07D413/12 , C07D417/14 , A61K31/4439 , A61K31/444 , C07D413/14
CPC分类号： C07D233/64 , C07D249/06 , C07D263/32 , C07D271/06 , C07D413/12
摘要： Compounds are provided which are useful as antidiabetic agents and antiobesity agents and have the structure wherein m is 0, 1 or 2; n is 0, 1 or 2; Q is C or N; A is (CH2)x where x is 1 to 5, or A is (CH2)x1 where x1 is 1 to 5 with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A is —(CH2)x2—O—(CH2)x3— where x2 is 0 to 5 and x3 is 0 to 5, provided that at least one of x2 and x3 is other than 0; B is a bond or is (CH2)x4 where x4 is 1 to 5; X is CH or N; X2 is C, N, O or S; X3 is C, N, O or S; X4 is C, N; O or S; X5 is C, N, O or S; X6 is C, N, O or S; provided that at least one of X2, X3, X4 X5 and X6 is N; and at least one of X2, X3, X4 X5 and X6 is C, and specifically excluding the structure(s) as shown below: where X2═N, X3═C, X4═O or S, Z=O or a bond R1 is H or alkyl; R2 is H, alkyl, alkoxy, halogen, amino or substituted amino or cyano; R2a, R2b and R2c may be the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino or cyano; and R3 and Y are as defined herein, which compounds are useful in treating diabetes and obesity.
-
3.发明申请Rifamycin C-11 oxime derivatives effective against drug-resistant microbes 有权对抗耐药微生物有效的利福霉素C-11肟衍生物公开(公告)号：US20050203076A1
公开(公告)日：2005-09-15
申请号：US11076172
申请日：2005-03-09
申请人： Jing Li , Charles Ding , Zhenkun Ma
发明人： Jing Li , Charles Ding , Zhenkun Ma
IPC分类号： A61K31/343 , C07D491/14
CPC分类号： C07D498/08 , A61K31/395 , A61K31/4427 , A61K31/4525 , A61K31/4709 , A61K31/496 , A61K31/5377 , C07D519/00
摘要： The invention relates to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the rifamycin derivatives having an oxime group at the C-11 position.
摘要翻译： 本发明涉及具有抗菌活性的利福霉素衍生物，包括抗药性微生物的活性，具体地，在C-11位具有肟基的利福霉素衍生物。
-
公开(公告)号：US08343944B2
公开(公告)日：2013-01-01
申请号：US12844748
申请日：2010-07-27
申请人： Yi Xia , Michael Richard Kevin Alley , Yasheen Zhou , Rajeshwar Singh , Charles Ding , Kathy Cao , Jacob J. Plattner , Ligong Ou , Guofeng Jia , Neerja Saraswat , Sreekanth Ramachandran , Ding Zhou
发明人： Yi Xia , Michael Richard Kevin Alley , Yasheen Zhou , Rajeshwar Singh , Charles Ding , Kathy Cao , Jacob J. Plattner , Ligong Ou , Guofeng Jia , Neerja Saraswat , Sreekanth Ramachandran , Ding Zhou
CPC分类号： C07F5/025 , A61K31/69 , A61K45/06 , A61K2300/00
摘要： This invention largely relates to 3,4,6-trisubstituted benzoxaborole compounds, and their use for treating bacterial infections.
摘要翻译： 本发明主要涉及3,4,6-三取代苯并恶唑化合物及其用于治疗细菌感染的用途。
-
公开(公告)号：US20200175607A1
公开(公告)日：2020-06-04
申请号：US16208155
申请日：2018-12-03
申请人： Charles Ding , Kebin Lu , Thomas Shieh
发明人： Charles Ding , Kebin Lu , Thomas Shieh
摘要： Segmentation algorithms may operate on vast quantities of data to segment the data into a useful data the model. The segmentation data model may then be applied to additional data that may be received in real time. Further, the real time data may be given a score based on the segmentation model and the desires of the user. The segmentation of the data and the score may be returned to a user and the user may determine if additional actions make logical sense based on the score and segmentation.
-
公开(公告)号：US08703742B2
公开(公告)日：2014-04-22
申请号：US13227444
申请日：2011-09-07
申请人： Vincent S. Hernandez , Charles Ding , Jacob J. Plattner , Michael Richard Kevin Alley , Fernando Rock , Suoming Zhang , Eric Easom , Xianfeng Li , Ding Zhou
发明人： Vincent S. Hernandez , Charles Ding , Jacob J. Plattner , Michael Richard Kevin Alley , Fernando Rock , Suoming Zhang , Eric Easom , Xianfeng Li , Ding Zhou
CPC分类号： C07F5/025
摘要： This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
摘要翻译： 本发明涉及苯并恶唑化合物及其用于治疗细菌感染的用途。
-
公开(公告)号：US20140324699A1
公开(公告)日：2014-10-30
申请号：US14263654
申请日：2014-04-28
申请人： Charles Ding , Aoyu Chen , Suyun Xu , Kevin Siegel
发明人： Charles Ding , Aoyu Chen , Suyun Xu , Kevin Siegel
IPC分类号： G06Q20/40
CPC分类号： G06Q20/4016
摘要： Embodiments of the invention relate in part to determining a testing model and providing a testing transaction score for transactions. The testing transaction score may indicate a likelihood that the transaction is a testing transaction. One embodiment of the invention discloses a method comprising receiving a first authorization message for a first transaction using an account, determining a testing transaction score for the first transaction using a testing model, and determining that the first transaction is a testing transaction based on the testing transaction score, wherein the testing transaction score for the first transaction is used for declining a second transaction using the same account conducted after the first transaction.
摘要翻译： 本发明的实施例部分地涉及确定测试模型并提供交易的测试交易分数。 测试交易分数可能表明交易是测试交易的可能性。 本发明的一个实施例公开了一种方法，包括使用帐户接收第一交易的第一授权消息，使用测试模型确定第一交易的测试交易得分，以及基于所述测试确定所述第一交易是测试交易 交易分数，其中第一交易的测试交易分数用于使用在第一交易之后进行的相同账户拒绝第二交易。
-
公开(公告)号：US20110136763A1
公开(公告)日：2011-06-09
申请号：US12844748
申请日：2010-07-27
申请人： Yi Xia , Michael Richard Kevin Alley , Yasheen Zhou , Rajeshwar Singh , Charles Ding , Kathy Cao , Jacob J. Plattner , Ligong Ou , Guofeng Jia , Neerja Saraswat , Sreekanth Ramachandran , Ding Zhou
发明人： Yi Xia , Michael Richard Kevin Alley , Yasheen Zhou , Rajeshwar Singh , Charles Ding , Kathy Cao , Jacob J. Plattner , Ligong Ou , Guofeng Jia , Neerja Saraswat , Sreekanth Ramachandran , Ding Zhou
CPC分类号： C07F5/025 , A61K31/69 , A61K45/06 , A61K2300/00
摘要： This invention largely relates to 3,4,6-trisubstituted benzoxaborole compounds, and their use for treating bacterial infections.
摘要翻译： 本发明主要涉及3,4,6-三取代苯并恶唑化合物及其用于治疗细菌感染的用途。
-
公开(公告)号：US20050261262A1
公开(公告)日：2005-11-24
申请号：US11034195
申请日：2005-01-12
申请人： Zhenkun Ma , Yafei Jin , Jing Li , Charles Ding , Keith Minor , Jamie Longgood , In Kim , Susan Harran , Keith Combrink , Timothy Morris
发明人： Zhenkun Ma , Yafei Jin , Jing Li , Charles Ding , Keith Minor , Jamie Longgood , In Kim , Susan Harran , Keith Combrink , Timothy Morris
IPC分类号： A61K31/33 , A61K31/395 , C07D491/14 , C07D498/08
CPC分类号： C07D498/00
摘要： Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.
摘要翻译： 本发明要求具有抗微生物活性的利福霉素衍生物，包括抗药性微生物的活性。 本发明的利福霉素衍生物是唯一设计的，因为它们具有通过利福霉素部分的C-3碳与连接基共价连接的利福霉素部分，接头又与治疗部分或抗菌剂/药效基团共价连接。 治疗部分可以是喹诺酮，恶唑烷酮，大环内酯，氨基糖苷，四环素核心或与抗菌剂相关的结构/药效团。
-
公开(公告)号：US20120115813A1
公开(公告)日：2012-05-10
申请号：US13227444
申请日：2011-09-07
申请人： Vincent S. Hernandez , Charles Ding , Jacob J. Plattner , Michael Richard Kevin Alley , Fernando Rock , Suoming Zhang , Eric Easom , Xianfeng Li , Ding Zhou
发明人： Vincent S. Hernandez , Charles Ding , Jacob J. Plattner , Michael Richard Kevin Alley , Fernando Rock , Suoming Zhang , Eric Easom , Xianfeng Li , Ding Zhou
CPC分类号： C07F5/025
摘要： This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
摘要翻译： 本发明涉及苯并恶唑化合物及其用于治疗细菌感染的用途。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.044 秒)